Pemrydi is the first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
The injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to specific factors.
Generic Precedex injection is indicated for the sedation of initially intubated and mechanically ventilated patients receiving treatment in an intensive care setting.
